Sjögren’s disease is a chronic autoimmune condition in which the immune system attacks the glands that produce moisture, most commonly causing dry eyes and dry mouth, along with fatigue, joint pain, and, in some people, damage to organs such as the kidneys and lungs. For decades, care has focused on relieving symptoms rather than altering the disease itself. That is now changing, and understanding Sjögren’s disease treatment today means looking at both the tools already in use and the wave of experimental therapies moving through trials.
Current Sjögren’s Syndrome Treatment
Sjögren’s syndrome treatment has historically relied on artificial tears, saliva substitutes, and medications like pilocarpine and cevimeline to stimulate gland function. For joint pain and fatigue, doctors often turn to hydroxychloroquine, and for more severe systemic involvement, off-label immunomodulators such as methotrexate or rituximab may be used. These approaches manage discomfort but do not reverse the underlying autoimmune process, which is why the field has long needed something better.
Sjögren’s Drugs and Available Treatment Options
Among current Sjögren’s drugs, none carry an approval specifically for modifying the disease course itself — every existing therapy is either symptomatic or borrowed from other autoimmune conditions. That leaves patients and clinicians choosing from a narrow set of Sjögren’s treatment options, often combining several therapies to address different symptoms simultaneously. This gap is a major reason so much research attention has shifted toward disease-modifying candidates.
New Sjögren’s Treatments and the Growing Pipeline
The most significant shift is the emergence of new Sjögren’s treatments designed to target the immune mechanisms driving the disease rather than just its symptoms. The Sjögren’s pipeline now includes more than 20 companies developing candidates, according to recent industry analysis, spanning B-cell depletion, BAFF-receptor inhibition, and neonatal Fc receptor blockade strategies.
Sjögren’s Clinical Trials Reaching Phase 3
Several Sjögren’s clinical trials have reached late-stage development in 2026. Novartis’s ianalumab became one of the first therapies to report positive Sjögren’s phase 3 trials, with its NEPTUNUS-1 and NEPTUNUS-2 studies both meeting their primary endpoint of reduced disease activity. Vor Biopharma’s telitacicept entered Phase 3 through the UPSTREAM SjD trial in mid-2026, and Janssen began two identical primary Sjögren’s syndrome trials for nipocalimab around the same time. Earlier-stage work continues too, with Immunovant’s IMVT-1402 and other candidates advancing through Sjögren’s phase 2 trials that build on mechanisms already validated by the leading Phase 3 programs.
Sjögren’s Research 2026: A Turning Point
This year has been described by researchers as a genuine inflection point. Sjögren’s research 2026 reflects, for the first time, phase 3 programs demonstrating measurable success when systemic disease activity is assessed with standardized indices. The Sjögren’s latest research also highlights lessons from past failed trials — namely the importance of enrolling patients with clearly active disease and using composite endpoints that capture systemic, symptomatic, and functional outcomes together.
Sjögren’s Biologics Leading the Charge
Much of this progress centers on Sjögren’s biologics. Ianalumab combines B-cell depletion with BAFF-receptor inhibition, while telitacicept blocks B-cell survival signals through a dual-target fusion protein. These Sjögren’s biologic therapies represent a distinct category from older Sjögren’s syndrome drugs, which were generally repurposed rather than purpose-built for this condition.
Sjögren’s Disease Market and Industry Involvement
Analysts are increasingly tracking the Sjögren’s disease market, anticipating that an approved disease-modifying therapy could reshape treatment standards for the first time. The broader Sjögren’s treatment market is expected to expand significantly if any of the current late-stage candidates gain regulatory clearance. A growing list of Sjögren’s disease companies — including Novartis, Janssen, Vor Biopharma, Immunovant, and Grifols — are now active in this space, alongside smaller Sjögren’s pharma companies pursuing earlier discovery-stage programs.
Sjögren’s Drug Development and What Comes Next
Overall Sjögren’s drug development has matured considerably, moving from single-mechanism symptomatic relief toward a more sophisticated understanding of immune-driven disease activity. Several Sjögren’s emerging therapies and Sjögren’s investigational drugs are now positioned to potentially reach approval within the next few years, and if the current front-runners succeed, a second generation of Sjögren’s pipeline drugs using similar mechanisms could follow close behind. For a condition that has waited decades for its first targeted therapy, the prospect of new Sjögren’s new medicines reaching patients marks a meaningful and long-awaited shift.
Related Reports Offered by Delveinsight
https://www.delveinsight.com/report-store/sjogrens-syndrome-pipeline-insight
https://www.delveinsight.com/report-store/sjogrens-syndrome-market-size
https://www.delveinsight.com/report-store/vay-736-sales-forecast-and-market-size-analysis